Anagrelide for control of myeloproliferative thrombocythaemia: Long- term experience in 6 patients;Anagrelide zur kontrolle der myeloproliferativen thrombozythamie: Langzeiterfahrung bei 6 patienten

Schweizerische Medizinische Wochenschrift

Volumn 128, Issue 46, 1998, Pages 1808-1812

  Burkhard, R ^a   Adam, H ^a   Widmer, L ^a   Honegger, H P ^a  

^a Stadtspital Triemli   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; HYDROXYUREA; INTERFERON;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG INDUCED DISEASE; EPISTAXIS; FEMALE; HUMAN; MALE; MYELOPROLIFERATIVE DISORDER; THROMBOCYTE COUNT; TRANSIENT ISCHEMIC ATTACK; TRANSITIONAL BLINDNESS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; QUINAZOLINES; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOCYTOSIS; TREATMENT OUTCOME;

EID: 0032517589     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Murphy S. Therapeutic dilemmas: Balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD). Thromb Haemos 1997; 78:622-6.
2. Balduini CL. Primary thrombocythemia: New drugs for an evolving disease. Haematologica 1992;77:297-301.
3. Barbui T, Finazzi G, Dupuy E, Kiladjian JJ, Brière J. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. Leukemia Lymphoma 1996;22:149-60.
4. Silverstein MN, Petit RM, Solberg LA, Fleming JS, Knight RC, Schacter LP. Anagrelide: A new drug for treating thrombocytosis. N Engl J Med 1988;318:1292-4.
5. Petit RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 1997;34:51-44.
6. Petrides PE, Trapp O, Beykirch MK. Anagrelide (Agrelin). Pharmakologisches Profil und klinische Anwendung. Onkologe 1997;3:298-302.
7. Silverstein MN. Diagnosis and treatment of polycythemia vera, agnogenic myeloid metaplasia, and primary thrombocythemia. In: Wiernik PH, Canellos GP, Kyle RA, Schiffer CA, Hrsg. Neoplastic diseases of the blood. New York: Churchill-Livingstone; 1984. p. 135.
8. Iland HJ, Laszlo J, Peterson P, Murphy S, Brière J, Weinfeld A, et al. Essential thrombocythemia: Clinical and laboratory characteristics at presentation. Trans Ass Am Phys 1983; 96:165-74.
9. Murphy S, Iland H, Rosenthal D, Laszlo J. Essential thrombocythemia: An interim report from the polycythemia vera study group. Semin Hematol 1986;23:177-82.
10. Solberg LA, Tefferi A, Oles KJ, Tarach JS, Petit RM, Forstrom LA, et al. The effects of anagrelide on human megakaryocytopoiesis. Br J Haematol 1997;99:174-80.
11. Mazur EM, Rosmarin AG, Sohl PA, Newton JL, Narendran A. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 1992;79:1931-7.
12. Spencer CM, Brogden RN. Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia. Drugs 1994;47:809-22.
13. Balduini CL, Bertolino G, Noris P, Ascari E. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica 1992;77:40-3.
14. Chintagumpala MM, Kennedy LL, Steuber CP. Treatment of essential thrombocythemia with anagrelide. J Pediatr 1995; 127:495-8.
15. Michiels JJ, Van Genderen PJJ. Essential thrombocythemia in childhood. Semin Thromb Hemost 1997;23:295-301.
16. Mughal TI. Primary thrombocythemia: A current perspective. Stem Cells 1995;13:355-9.